Key Highlights
- In intraday market data on Tuesday, November 17, 2026, shares gained 24.53%, reaching USD 4.67, and no company announcement dated that day accounts for the move.
- According to the company, the FDA's June 1, 2026 complete response letter on CTx-1301 sought chemistry, Manufacturing and controls details and flagged no clinical safety or efficacy issues.
- Cash stood near USD 23.2 million at September 30, 2026, against USD 11.0 million at the end of 2025, while the third-quarter net loss was USD 7.7 million, compared with USD 7.3 million a year before.
- Management plans to resubmit between December 2026 and January 2027; the review goal is two months for a Class 1 resubmission and six months for Class 2.
A 24.53% Rise Without a Same-Day Announcement
On Tuesday, November 17, 2026, intraday market data had Cingulate (NASDAQ:CING) climbing 24.53%, to a price of USD 4.67. Company releases, filings and published coverage were searched, and none dated November 17 explains the rise, so the cause stays unconfirmed. The latest company news was the third-quarter report of November 13, 2026, and published coverage said the stock slid 12.8% on the day it appeared; some of the recent gain could therefore be a rebound, which is an inference and not a reported reason. The clinical-stage biopharmaceutical company is developing CTx-1301, a dexmethylphenidate tablet aimed at attention Deficit hyperactivity disorder (ADHD).
From the Complete Response Letter Toward a Resubmission
The new drug application carried an FDA target action date of May 31, 2026, and the agency issued a complete response letter on June 1, 2026, the company reports. It requested further chemistry, manufacturing and controls information; the company says the letter raised no clinical safety or efficacy concerns. Cingulate and its contract manufacturer have substantially completed the manufacturing work, in the company's words, and a resubmission is planned between December 2026 and January 2027, with the possibility of an earlier date. A Class 1 designation brings a two-month review goal, whereas Class 2 brings six months. For Cingulate (NASDAQ:CING), a launch could start in the third quarter of 2027 if approval comes, a company timeline that depends on the FDA review.
Cash Runway, Share Dilution and the Price of Waiting
The third-quarter net loss was USD 7.7 million versus USD 7.3 million a year ago, and the nine-month loss reached USD 22.9 million versus USD 16.2 million. Spending on commercial readiness pushed selling, general and administrative expense up 45.5% to USD 4.6 million, whereas Research and Development edged up 2.2% to USD 2.9 million. The company says cash of about USD 23.2 million at September 30, 2026 funds operations into mid-2027, following a first-quarter private Placement of USD 12.0 million, and a further USD 22.5 million raised this year through two arrangements, namely an at-the-market Facility and a purchase deal with Lincoln Park Capital. Cingulate (NASDAQ:CING) sells new shares through those programs, which dilutes existing holders. At this size, a few trades can move the price, spreads can widen and quoted moves can reverse.
Where Things Stand
The 24.53% advance has no confirmed trigger, so the cause is unknown. Cingulate (NASDAQ:CING) has yet to resolve the manufacturing questions in its complete response letter, must get its application back to the FDA by January 2027, and holds roughly USD 23.2 million of cash against a USD 7.7 million quarterly loss. Next to watch are the resubmission, the FDA's Class 1 or Class 2 decision, more stock sales under the two financing programs, and whether the price holds when no company news accounts for the jump.
_11_17_2026_18_59_44_560836.jpg)





Please wait processing your request...